ReviewJournal of endocrinological investigation2022
Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
G Iacobellis et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papertrialcites it